BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
April 30 2019 - 4:00AM
Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading
developer of adult stem cell therapeutics for neurodegenerative
disease, today announced that it has expanded its proprietary
cellular technology platform to include NurOwn®-derived exosomes
for potential development across a broad range of CNS (Central
Nervous System) disorders.
Exosomes are nano-sized (30–120 nm),
cell-derived vesicles that exhibit remarkable stability and may
provide enhanced cell-to-cell delivery of bio-active molecules
across the blood brain barrier into difficult to reach regions of
the brain. Exosomal cargo provides important regulatory
functions for many cell processes, including immunomodulation and
neuroprotection.
“BrainStorm is leveraging cutting edge science
and technology to continually explore and advance breakthrough
scientific solutions,” said Revital Aricha PhD, BrainStorm’s VP
R&D. She added, “We are actively developing our proprietary
exosome technology as an ideal nano-carrier to effectively deliver
bio-active molecules to the brain in a non-invasive manner, and
leverage their exceptional biological properties, simplified
long-term storage and transport which may facilitate repeat dosing
as a potential allogeneic product in chronic neurodegenerative
disease.”
“BrainStorm is committed to the development of
highly innovative therapies for devastating neurodegenerative
diseases,” said Chaim Lebovits, BrainStorm’s CEO. “We believe that
exosomes have significant therapeutic potential in
neurodegenerative disease through their unique biological
characteristics, customizable cargo, and intrinsic ability to
target specific CNS pathways. We plan to provide periodic business
updates as we advance our R&D pipeline efforts and identify the
lead indication for clinical evaluation.”
About BrainStorm Cell Therapeutics
Inc.
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm is currently enrolling a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA
clearance to initiate a Phase 2 open-label multicenter trial in
progressive Multiple Sclerosis. The Phase 2 study of autologous
MSC-NTF cells in patients with progressive MS (NCT03799718) started
enrollment in March 2019. For more information, visit the company's
website at www.brainstorm-cell.com.
Safe-Harbor Statement
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS
Corporate: Uri YablonkaChief Business Officer BrainStorm Cell
Therapeutics Inc.Phone: +1 646.666.3188 uri@brainstorm-cell.com
Media:Sean LeousWestwicke/ICR PR Phone:
+1.646.677.1839sean.leous@icrinc.com
Investors:Michael LevitanSolebury TroutPhone:
+1.646.378.2920mlevitan@soleburytrout.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024